FDA clears brain mapping tool for neuromodulation therapies

The FDA has approved Turing Medical's automated brain mapping technology, Bullsai Identify, which helps doctors create personalized plans for neuromodulation therapies, like deep brain stimulation (DBS), for conditions such as Parkinson’s disease. Using AI, the platform analyzes advanced brain imaging to generate detailed maps of a patient's brain, helping doctors target the best areas for treatment. Damien Fair, co-founder of Turing Medical, views this approval as a validation of their precision medicine approach, aiming to make brain mapping more accessible in clinical settings. DBS is a treatment for Parkinson's when medications are no longer effective, using electrical impulses to modify brain activity, though the exact mechanism is unclear. Traditional brain therapies often rely on generalized brain maps, which may result in incorrect targeting and side effects. Bullsai Identify addresses this by creating custom maps based on each person’s unique brain structure, potentially leading to more precise treatments and fewer side effects. Turing Medical's Bullsai program also includes other tools like Bullsai Enhance, a real-time MRI monitoring system to improve scan quality, and Bullsai Confirm, which ensures accurate placement of electrodes during neuromodulation therapy.